- $14.53m
- $16.61m
- $2.29m
Brief: Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
Brief: Femasys Closes $8 Million In Financing To Accelerate Commercialization Of Fertility And Birth Control Portfolios
Femasys Inc expected to post a loss of 14 cents a share - Earnings Preview
Femasys Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Femasys Secures First European Order For Fembloc, Marking Strategic Milestone In Global Expansion
Femasys Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Femasys Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Femasys Achieves Australian & New Zealand Regulatory Approvals For Femaseed For First-Line Infertility Treatment And Femvue Diagnostic
Brief: Femasys announces European Approval for Fembloc®, First Non-Surgical Permanent Birth Control
Brief: Femasys Announces Pricing Of Underwritten Public Offering And Concurrent Private Placement With Gross Proceeds Of $4.5 Million
Brief: Femasys Announces Proposed Public Offering Of Common Stock And Concurrent Private Placement
Brief: Femasys Inc. FY EPS USD -0.85
Brief: Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
Brief: Femasys Announces Issued U.S. Patent Covering FemBloc Device For Female Permanent Birth Control
Brief: Femasys Secures Strategic Distribution Partnerships For Commercialization Of FemaSeed For Over $1.3 Mln In Spanish Market
Brief: Femasys Announces CE Mark And Canadian Approval For Femvue® Mini
U.S. RESEARCH ROUNDUP-Agenus, Guardant Health, Zoetis
Brief: Femasys Completes First In-Office Commercial Procedure With FDA-Cleared FemaSeed Infertility Solution
Brief: Femasys Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center